ClinicalTrials.gg
CompletedNCT06650761Updated May 4, 2026

A Phase I Study of CDX-622

A Phase 1 interventional study of CDX-622 and Normal Saline in Healthy Participants, sponsored by Celldex Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Celldex Therapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a study to determine the safety of CDX-622 in healthy participants.

Read the detailed description

CDX-622 is a bispecific antibody that binds to stem cell factor (SCF) and thymic stromal lymphopoietin (TSLP).

This study will evaluate the safety, pharmacokinetics, and Pharmacodynamics of IV single ascending doses (Part 1), IV multiple ascending doses (Part 2), and subcutaneous (SC) single ascending doses (Part 3) of CDX-622 in healthy participants.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Celldex Therapeutics is the lead sponsor of 45 studies on the registry; 3 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 1 (7%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • An signed and dated by the participant.
  • Healthy volunteer aged 18-55.
  • In generally good health and without significant medical conditions based on physical exam, , and laboratory test results.
  • (BMI) ≥ 18 kg/m2 to ≤ 32 kg/m2.
  • No course of medication, whether prescribed or over the counter, in the 4 weeks before study drug administration.
  • Both males and females of must agree to use a medically accepted regimen during study and up to 150 days afterwards.
  • Not a current smoker (or regular user of any nicotine containing product).
  • Willing to follow all study rules.

Key Exclusion Criteria:

  • Women who are pregnant or nursing.
  • History of anaphylaxis, food allergies, or allergies (chronic or seasonal) requiring prescription medication.
  • History of asthma requiring the use of inhaled medication within the past 5 years.
  • Vaccination within 4 weeks prior to study drug administration (subjects must agree to avoid vaccination during the study).
  • Blood donation (excluding plasma donation) of approximately 500 mL within 56 days prior to Screening.
  • Positive urine test for alcohol and drugs of abuse.

Additional protocol defined inclusion and exclusion criteria could apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    CDX-622

    Eligible participants will receive doses of CDX-622 by IV or SC

    Drug: CDX-622

  • Placebo comparator
    Normal Saline

    Eligible participants will receive doses of Normal Saline by IV or SC

    Drug: Normal Saline

Interventions

  • DrugCDX-622

    Up to 4 infusions of one of seven dosages of CDX-622 or up to 1 dose by subcutaneous injection of one of three dosages of CDX-622

  • DrugNormal Saline

    Up to 4 infusions or 6 SC injections of normal saline

06

What researchers measure

Primary outcomes

  1. Safety as assessed by Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Trials. Infusion reactions will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

    To evaluate the safety profile as determined by the incidence of adverse events in single or multiple ascending doses of CDX-622 or placebo comparator in healthy participants.

    Time frame: Day 1 up to Day 127

Secondary outcomes

  1. CDX-622 serum evaluations over time

    CDX-622 serum concentrations will be measured at specified visits

    Time frame: Day 1 up to Day 127

  2. CDX-622 biomarker evaluations over time

    The effect of CDX-622 on serum tryptase levels and other relevant biomarkers

    Time frame: Day 1 up to Day 127

  3. Measurement of anti-drug antibody development over time

    Participants will be monitored for the development of anti-drug antibodies

    Time frame: Day 1 up to Day 127

07

Study locations

1 site
  • Celerion, Inc.
    Tempe, Arizona 85283, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Apr 2026, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2024
First posted
Oct 21, 2024
StartActual
Nov 1, 2024
Primary completionActual
Apr 24, 2026
CompletionActual
Apr 24, 2026
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06650761
Responsible party
Sponsor
First posted
Oct 21, 2024
Start date
Nov 1, 2024
Primary completion
Apr 24, 2026
Completion
Apr 24, 2026
Last update
May 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion